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Introduction
Successful responses of the immune system against tumor cells are frequently hindered by the presence of an immunosuppressive tumor microenvironment (1) . A series of mechanisms prevent the recognition of tumor-associated antigens presented by tumor cells from activating a productive response able to clear transformed cells. Several processes have been described to contribute to the immune escape that allows tumor cells to block anti-tumor immunity including, among others, the down-regulation of antigen presentation by tumor cells and the expression of suppressor factors or the recruitment of cells with suppressor activity (1) (2) (3) (4) (5) . One of the effects reported to occur in the tumor microenvironment is the induction of antigen-specific tolerance in CD4+ and CD8+ T cells (6, 7) . Several mechanisms have been proposed to account for the anergic phenotype of tumor antigen-specific T cells. Ligation of inhibitory receptors and defective activation of antigen presenting cells, among others, appear to contribute to the establishment of a hypo-responsive state in tumor specific T cells (3, 8) . Dendritic cells (DC) in tumor microenvironments appear to play a crucial role in the induction of anergy in CD4+ T cells (9) . Several models of intrinsic T cell hyporesponsiveness have been proposed, each regulated by a specific set of molecular mechanisms that maintain T cells anergic (10, 11) .The factors that determine which mechanisms are activated in vivo in a given context or how they may regulate specific processes is currently unknown. When stimulated through engagement of their antigen receptor in the absence of co-stimulatory signals, CD4+ T cells become anergic to subsequent re-stimulations. Their hypo-responsive state is characterized by decreased proliferative response and reduced cytokine production following re-stimulation even in the presence of costimulation. Clonal anergy in CD4+ T cells is established as a result of the activation of a program of gene expression that is dependent on the transcription factor NFAT. Proteins encoded by those genes are responsible for the maintenance of an unresponsive state. This is accomplished through the inhibition of signaling pathways downstream of the TCR and through direct repression of cytokine gene expression (12) . Little is known however on the mechanisms show that tumor antigen specific CD4+ T cells are rendered anergic in vivo through a mechanism that requires NFAT1 activity and involves the expression of anergy specific genes.
Furthermore, by specifically targeting the regulation of anergy induction using NFAT1-deficient mice, our results support that tumor-induced CD4+ T cell anergy participates in the evasion of anti-tumor responses, as NFAT1-deficient T cells become resistant to tumor-induced anergy, delaying tumor appearance and slowing tumor growth. 
Materials and Methods

Mice
C57Bl/6, B6.Pl-Thy1 a /CyJ, B6.Cg-Tg(TcraTcrb)425Cbn/J (OT-II), B6.129S2-Cd8a tm1Mak /J, BALB/c, and BALB/c-Tg(DO11.10)10Loh/J mice were purchased from Jackson Laboratories.
Nfat1
-/-OT-II mice were generated by crossing B6.Nfat1 -/-(13) with OT-II mice. Nfat1 -/-DO11.10 mice were generated by crossing BALB/c.Nfat1 -/-with DO11.10 mice. Mice were maintained in pathogen-free conditions. All animal work was performed according to the guidelines of the Institutional Animal Care Committee at the Albert Einstein College of Medicine.
Tumor cell lines
The B16-F1 melanoma and EG7 thymoma cell lines were purchased from the American Type Culture Collection (ATCC). Cells received from the ATCC were not re-authenticated and were used within two months after receiving them. The B16-OVA cell line was a gift from EM Lord (University of Rochester Medical Center, NY). The lung carcinoma TC-1 cell line was a gift from TC Wu (Johns Hopkins University, MD). These cell lines were not genetically authenticated, but melanin production was assessed by microscopy and OVA expression confirmed by real time PCR. Cells were cultured in DMEM supplemented with 10% FBS, 2mM L-glutamine, 250IU
Penicillin/Streptomycin, and 50μM β-mercaptoethanol. For tumor injections, 5x10 5 
cells in
Hank s Balanced Salt Solution were injected subcutaneously into either the intrascapular or the lumbar regions. Where indicated mice were vaccinated with apoptotic cells prepared by irradiating TC-1 cells (10 7 /ml in PBS) with 10,000 rads. Mice were injected intraperitoneally with 100 μl of irradiated cell suspension mixed with equal volumes of incomplete Freund's adjuvant.
Vaccinations were performed once a week starting 2 weeks prior to tumor injections. Tumor growth was recorded by measuring perpendicular diameters and the volumes were calculated as π/6x1.6x(length x width) 3/2 . Primary CD4+ T cell isolation and culture CD4+ T cells were isolated using antiCD4-coupled magnetic beads (Invitrogen). To generate Th1 cells, CD4+ T cells were stimulated with plate bound anti-CD3ε (0.25μg/ml) and anti-CD28 (0.25μg/ml) antibodies (BD Biosciences), and differentiated with 10ng/ml of mouse IL-12 (eBioscience), 10μg/ml of blocking anti-mouse IL-4 antibody, and 10U/ml recombinant human IL-2 (Biological Resources Branch of the National Cancer Institute) for 6 days. Cells were cultured in DMEM supplemented with 10% FBS, 2mM L-glutamine, 50μM β-mercaptoethanol, essential vitamins, 550nM L-Arg, 240nM L-Asn, and 14nM folic acid.
Adoptive transfer and re-isolation of T cells
Nfat1
-/-or Nfat1
OT-II na ve CD4+ or in vitro differentiated OT-II Th1 cells were adoptively transferred (5x10 6 cells per mouse) into the tail veins of B6.PL-Thy1 a mice or CD8-deficient mice. Where indicated, adoptively transferred cells were re-isolated using a biotinylated anti-CD90.2 antibody and streptavidin coated magnetic beads (Invitrogen).
Isolation of tumor infiltrating T cells
Tumors were resected from mice and minced to 1-3mm fragments, then treated with 1mg/ml collagenase-D (Roche) and DNase-I (40U/ml, Sigma) in RPMI and incubated at 37 C for 1 hour.
Cells were then passed through a 40μm-mesh, washed and T cells isolated using antiCD4-coupled magnetic beads. 
Statistical Analysis
Differences between groups were analyzed with Student s t test. 
Results
Tumor-specific CD4+ T cells become hyporesponsive and produce less IL-2
To characterize tumor-induced hyporesponsiveness in antigen-specific CD4+ T cells, we When B16-OVA growth kinetics was analyzed, we did not observe any significant differences between mice that received either of those two T cell populations, indicating that tumor-specific CD4+ T cells could not mount an efficient anti-tumor response (Fig. 1B) . To rule out that this effect could be specific to B16 melanoma, similar experiments were performed using the more immunogenic EG7-OVA thymoma cell line. T cells isolated from DLN also showed decreased production of IL-2, which correlated with an inability of OT-II cells to control EG7-OVA growth (Suppl. Fig. 1A 
-B).
Studies have shown that Th1 skewing of CD4+ T cell populations is associated with antitumor immunity (14) . We therefore determined whether tumor-specific Th1 cells could control tumor growth better than na ve cells. Experiments similar to those described above were carried 
B16-OVA specific CD4+ T cells activate an anergy-associated program of gene expression characteristic of clonal anergy
To further validate our findings, we injected B16-OVA cells into the lumbar flanks of OT-II mice and compared responses of tumor-specific T cells that could have been presented with tumor antigen (isolated from inguinal DLN) and T cells that likely had no contact with melanoma antigens (isolated from distal cervical non-DLN). CD4+ T cells from DLN produced significantly lower amounts of IL-2, IFN-γ, and IL-17 compared to non-DLN ( Fig. 2A-C) . Ruling out these results could respond to Th2-skewing, IL-4 production was not detected at significant amounts in either location (Fig. 2D) . In addition, CD4+ T cells isolated from DLN were also hypoproliferative compared to T cells obtained from non-DLN (Fig. 2E ).
Clonally anergic T cells activate a program of gene expression that leads generates proteins responsible for inhibiting TCR-mediated signaling and activation-induced cytokine expression (12) . To determine if a similar mechanism was responsible for tumor-induced anergy, we assessed the expression of several anergy-associated genes in T cells isolated from DLN of B16-OVA bearing mice and compared it to T cells obtained from non-DLNs of the same mice. Confirming our hypothesis, T cells from DLN upregulated expression of 6 out of 7 different genes we assayed, including the E3 ubiquitin ligases Grail, Cblb and Itch, the transcription factors Egr2 and Grg4, and Caspase3 (Fig. 2F ).
Tumor infiltrating T cells isolated from tumors that had grown for 9 days in OT-II mice also produced much lower levels of IL-2 than cells isolated from non-DLN or spleen, and interestingly even less than cells from DLN ( Fig. 3A and data not shown) . Analysis of RNA extracted from the tumor infiltrating CD4+ T cells revealed also highly upregulated expression of Grail (Fig. 3B) .
We observed no significant differences in the percentages of CD25+CD4+ T cells or Foxp3 expression between DLN and non-DLN or spleens (data not shown), ruling out the possibility that decreased CD4+ T cell responses in these mice might be due to increased regulatory T cells (Treg) recruitment. (Fig. 4A-C) . However, CD4+ T cells from DLN of
B16-OVA specific
Nfat1
-/-OT-II mice failed to become anergic and produced similar (IL-2) or even higher (IFNγ) levels of Th1 cytokines than cells isolated from non-DLN (Fig. 4A-B) . IL-17 production was, 
however, also reduced in the DLN of Nfat1 -/-OT-II mice (Fig. 4C) . Interestingly, there were also OT-II Th1 cells (Fig. 5C ). Additionally, we confirmed that the observed effect on tumor onset in Nfat1 -/-OT-II mice was caused by the presence of tumor-specific CD4+ T cells, as tumors implanted in non-transgenic Nfat1 -/-mice behaved similarly than those injected in wildtype mice (Fig. 5D ). The capacity of anergyresistant NFAT1-deficient T cells to control tumor growth appeared to reside in their ability to regulate the activity of CD8+ T cells, as no significant differences in B16-OVA growth were detected when Nfat1 +/+ or Nfat1 -/-CD4+ T cells were transferred into B16-OVA-bearing CD8-deficient host mice (Fig. 5E ).
To exclude the possibility that the effects observed using B16-OVA could be specific for this cell line or the expression of OVA, we performed experiments using the lung cancer TC-1 cell (Fig. 6A) . Then we compared TC-1 growth in previously vaccinated wildtype and Nfat1 -/-deficient C57Bl/6 mice. Nfat1 -/-mice also showed significantly delayed growth of TC-1 tumors, supporting the role of NFAT1 in the establishment of tumorinduced tolerance (Fig. 6B) . We obtained similar results when experiments were performed in mice challenged with the EG-7-OVA thymoma cell line (Suppl. Fig. 1 ). 
Discussion
Transformed cells can express tumor-associated antigens that should be recognized as non-self by T cells and elicit effective anti-tumor responses. However, immunosuppressive mechanisms are engaged in the tumor microenvironment that account for the frequently inefficient anti-tumor T cell response (1, 4) . Tumor-specific CD4+ T cells can be rendered hyporesponsive by both solid and hematologic cancers (6, 16) . Using a B16-melanoma model, our data supports that tumor-specific T helper cells become anergic and show reduced ability to secrete several effector cytokines, including IL-2, IFNγ and IL-17. In addition, this hyporesponsive state bears similarity to the induction of clonal anergy as it is dependent on the transcription factor NFAT1, and leads to the up-regulation of clonal anergy associated genes.
Several models have been proposed to explain how T cells become anergic, including
clonal anergy and adaptive tolerance. These processes respond to the inactivation of distinct signaling pathways and also differ in the requirement for continuous antigen presence (10) (11) (12) .
Little is known about the specific physiological contexts in which different forms of T cell inactivation may occur. Our results indicate that a hyporesponsive state similar to clonal anergy is induced by cancer cells in antigen specific CD4+ T cells, and therefore identify clonal anergy as a mechanism of tumor-induced hyporesponsiveness in vivo. Clonally anergic T cells not only secrete less cytokines and proliferate less when stimulated but they also upregulate the expression of anergy-associated genes (11, (17) (18) (19) (20) (21) (22) (23) (24) . Our studies show that B16-OVA antigenspecific CD4+ T cells isolated from tumor DLN upregulate the expression of several anergy associated genes, including Grail, Itch, Cblb, Casp3, Grg4 and Egr2, supporting that T cells that have seen the tumor antigens become anergic.
It has been previously shown that DCs fail to properly activate in the tumor microenvironment and show decreased expression of B7 costimulatory ligands (3, 15, 25) . The transcription factor NFAT1 is critical for the induction of T cell anergy. Nfat1 -/-mice show T cell hyper-reactivity (13), and CD4+ T cells from these mice are resistant to anergy in vitro (11) . We were able to confirm that NFAT1 was also required for the induction of anergy in vivo using the soluble peptide-induced model of anergy. This in vivo observation provided us with a tool to study the significance of CD4+ T cell anergy in the context of tumor tolerance. CAN-11-3775 anergy-associated genes and maintaining levels of IL-2 and IFNγ expression, which supports that tumor-induced Th1 cell anergy is also dependent on NFAT1 activity. Although additional experiments will be required to address this discrepancy, it is possible that the expression of those genes in Th17 cells may still be regulated by calcium/NFAT signaling, but that these cells may be less dependent on NFAT1 and able to express anergy genes through the activation of other NFAT family members.
Functionally, CD4+ T cells isolated from the DLN of
Underscoring the importance of CD4+ T cell activity in orchestrating effective anti-tumor responses, our results show that mice harboring B16-OVA-specific TCR transgenic Nfat1 -/-CD4+ T cells delay the onset of tumor appearance and decrease the rate of growth. These effects were not observed in Nfat1 -/-mice with a wildtype TCR repertoire, suggesting that this was indeed an antigen and CD4+ T cell specific effect. It is likely that the delay in tumor growth was due to augmented CD8+ T cell responses due to increased CD4+ T cell activity, NFAT1- 
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